Founded in 2011, OMNI Pharma（OMNI）is a high-tech innovative pharmaceutical company focusing on drug delivery technologies.
Technical focus and expertise: The company is dedicated to the research and development, and industrialization of inhalation formulations, with a level of expertise comparable to that of top pharmaceutical companies in Europe and America. At present, the company has the capability of independent R&D and manufacturing of metered dose inhaler, dry powder inhaler, inhaled nebulizing solutions and nasal spray, and has a proprietary design platform incorporating breathing apparatus.
Product coverage：With treatment focus on asthma and chronic obstructive pneumonia (COPD), the company has product pipelines covering all key areas in this field, and the market potential is huge.
Government support: The dry powder formulation project has been designated the National Key Science and Technology Project and received strong government support. Since the beginning of 2019, a number of the company’s projects have entered the clinical trial stage, with the expectation that international-level inhalation formulations independently developed by China will soon be launched in domestic market.
Global Vision: The company is focusing on the expansion of overseas markets, together with domestic and foreign pharmaceutical companies and partners. The company is also actively promoting the launch of its products in mature markets, such as Europe and the U.S., as well as the China market,
"Made in China, for the World": Our standard and goal is to provide high-quality and affordable drugs for people across China and beyond.